Zanubrutinib, BGB-11417, BGB-11417, BGB-11417, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, BGB-11417, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets
BGB-11417-304
Phase 3 small_molecule active
Quick answer
Zanubrutinib, BGB-11417, BGB-11417, BGB-11417, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, BGB-11417, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets for treatment-naive Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- treatment-naive Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active